Literature DB >> 18456769

Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

J-L Harousseau1, M Dreyling.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18456769     DOI： 10.1093/annonc/mdn088

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  Bortezomib: a review of its use in patients with multiple myeloma.

Authors:  Monique P Curran; Kate McKeage
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 2.  Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Bortezomib induces heme oxygenase-1 expression in multiple myeloma.

Authors:  Lawrence N Barrera; Stuart A Rushworth; Kristian M Bowles; David J MacEwan
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

4.  Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.

Authors:  Kari Remes; Pekka Anttila; Raija Silvennoinen; Mervi Putkonen; Hanna Ollikainen; Venla Terävä; Marjatta Sinisalo; Kristiina Kananen; Frida Schain; Päivi Castren-Kortegangas; Tiina M Järvinen; Marta Pisini; Felix Wahl; Tricia Dixon; Amy Leval
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

5.  Prevalence of p16 methylation and prognostic factors in plasma cell myeloma at a single institution in Korea.

Authors:  Hyunjung Kim; Dong Wook Jekarl; Myungshin Kim; Yonggoo Kim; Jihyang Lim; Kyungja Han; Chang-Ki Min
Journal:  Ann Lab Med       Date:  2012-12-17       Impact factor: 3.464
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.